Emerging drugs for adrenocortical carcinoma

Expert Opinion on Emerging Drugs

Volumn 13, Issue 3, 2008, Pages 497-509

  Berruti, Alfredo ^a   Ferrero, Anna ^a   Sperone, Paola ^a   Daffara, Fulvia ^b   Reimondo, Giuseppe ^b   Papotti, Mauro ^b   Dogliotti, Luigi ^a   Angeli, Alberto ^b   Terzolo, Massimo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Adrenocortical carcinoma; Chemotherapy; Mitotane; Target therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 690514; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FLORIDEF; FLUDROCORTISONE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GLUCOCORTICOID; MITOTANE; PACLITAXEL; SOMATOMEDIN RECEPTOR INHIBITOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TARIQUIDAR; TIPIFARNIB; UNCLASSIFIED DRUG; VALSPODAR; VINCRISTINE;

ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; NEUROTOXICITY; PATIENT CARE; REVIEW; SIDE EFFECT;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; MITOTANE;

EID: 53549126060     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.3.497     Document Type: Review

References (90)

1. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711-36
2. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-26
3. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;60:273-87
4. Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28
5. Schteingart DE. Current perspective in the diagnosis and treatment of adrenocotrical carcinoma. Rev Endocr Metab Disord 2001;2:323-33
6. Phan AT. Adrenal cortical carcinoma: review of current knowledge and treatment practices. Hematol Oncol Clin North Am 2007;21:489-507
7. Soon PS, Libe R, Bean DE, et al. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg 2008;247:157-64
8. Almeida MQ, Latronico AC. The molecular pathogenesis of childhood adrenocortical tumors. Horm Metab Res 2007;39:461-6
9. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001;98:9330-1
10. Macfarlane DA. Cancer of the adrenal cortex: the natural history, prognosis, and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958;23:155-86
11. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978;120:660-5
12. Icard P, Goudet P, Charpenay C, et al. Adrenocotrical carcinomas: surgical trends and results of a 253 patients series from the French Association of Endocrine Surgeons Study Group, World J Surg 2001;25(7):891-7
13. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119(2):161-70
14. Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997;122(6):1212-8
15. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-80
16. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-26
17. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963-70
18. Schteingart DE, Motazedi A, Noonan RA, et al. Treatment of adrenal carcinomas. Arch Surg 1982;117:1142-6
19. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-50
20. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5
21. Fassnacht M, Hahner S, Koscher AC, et al. The German Adrenocortical Cancer Registry. Analysis of the first 333 patients. Abstracts of the 88th annual meeting of the Endocrine Society; 2006; P2 781
22. Schteingart DE, Doherty GM, Gauger TJ, et al. Management of patients with adrenal cancer: recommendation of an international consensus conference. Endocr Relat Cancer 2005;12(3):667-80
23. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001;92(5):1113-21
24. Hahner S. Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6(4):386-94
25. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72(11):3145-55
26. Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. Cancer 1989;64(3):765-9
27. Luton JP, Cerdas S, Billand L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322(17):1195-201
28. Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991;1106:1006-13
29. Haak HR, Hermans J, Van De Velde CJ. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;947-51
30. Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: Experience in 45 patients. Oncology 1997;54:490-6
31. Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000;88(5):1159-65
32. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenilchloroetane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;1385-92
33. Terzolo M, Pia A, Berruti A, Osella G, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000;2234-8
34. Van Slooten H, Moolenaar AJ, Van Seters AP, et al. The treatment of adrenocortical carcinoma with o,p'DDD: prognostic simplifications of serum level monitoring. Eur J Cancer Clin Oncol 1984;20:47-53
35. Ahlman H, Khorram-Manesh A, Jansson S, et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001;25(7):927-33
36. Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004;60:273-87
37. Bates SE, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/ P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73(1):18-29
38. Villa R, Orlandi L, Berruti A, et al. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999;14(1):133-8
39. Abraham JS, Bakke A, Rutt B, et al. A Phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94(9):2333-43
40. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11(10):1281-7
41. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998;83(10):2194-200
42. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr Relat Cancer 2005;12(3):657-66
43. Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998;78(4):546-9
44. Bukowski RM, Wolfe M, Levine HS, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993;11(1):161-5
45. Schlumberger M, Brugieres L, Gicquel C, et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991;67(12):2997-3000
46. Van Slooten H, Van Oosterom AT. CAP (cyclophosphamide, doxorubidn, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983;67(4):377-9
47. Burgess MA, Legha SS, Sellin RV. Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc Ann Soc Clin Oncol 1993;12
48. Menefee M, Edgerly M, Velarde M, et al. The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC). Proc Ann Soc Clin Oncol 2006;24
49. Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2001;1191-6
50. Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma. New Engl J Med 2007;357(12):1256-7
51. Rodger SE, Evans DB, Lee JE, et al. Adrenalcortical carcinoma. Surg Oncol Clin N Am 2006;15(3):535-53
52. This information is available as a free service in Europe, provided by the company distributing mitotane: Available from: infoλysodren-europe.com
53. Martin LP, Hamilton TC, Schilder RJ. Platinum resistence. The role of DNA repair pathways. Clin Cancer Res 2008;14(5):1291-5
54. Barlaskar FM, Hammer GD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 2007;8(4):343-8
55. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr-Relat Cancer 2006;13(Suppl 1):S33-43
56. Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28(1):20-47
57. Hotta M, Baird A. Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. Proc Natl Acad Sci USA 1986;83:7795-9
58. Feige JJ, Cochet C, Savona C, et al. Transforming growth factor beta 1: an autocrine regulator of adrenocortical steroidogenesis. Endocr Res 1991;17:267-79
59. De Fraipont F, El Atifi M, Gicquel C, et al. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab 2000;85:4734-41
60. Ilvesmaki S, Kahri AI, Miettinen PJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993;77:852-8
61. Vittet D, Ciais D, Keramidis N, et al. Paracrine control of the adult adrenal cortex vasculature by vascular endothelial growth factor. Endocr Res 2000;26(4):843-52
62. Weber MM, Auerhammer CJ, Kiess W, et al. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 1997;136(3):296-303
63. Turner HE, Harris AL, Melmed S, et al. Angiogenesis in endocrine tumors. Endocr Rev 2003;24(5):600-32
64. Bernini A, Morerti AG, Bonadio M, et al. Angiogenesis in Human Normal and Pathologic Adrenal Cortex. J Clin Endocrinol Metabol 2002;87(11):4961-5
65. Allolio B. Tissue Arrays as Tools to Identify New Treatment Targets. International Adrenal Cancer Symposium, Ann Arbor; 14-25 March, 2008; personal presentation
66. First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT). Available from: www.firm-act.org
67. Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001;92:1577-90
68. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749-58
69. Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumor model can restore anticancer drug efficacy. Eur J Cancer 2001;40:594-605
70. Martin C, Berridge G, Mistry P, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403-11
71. Samnotra V, Vassilopoulou-Sellin R, Fojo AT, et al. A Phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Proc Ann Soc Clin Oncol 2007;25
72. Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; in press
73. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
74. Hammer G. Wnt Signaling in Adrenocortical Stem Cells and ACC. International Adrenal Cancer Symposium Ann Arbor; 2008; personal presentation
75. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008;15:1-6
76. Lee JE, Berger DH, El-Naggar AK, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118:1090-8
77. Henley DJ, Van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma: a continuing challenge. Surgery 1983;94:926-31
78. Bodie J, Novick AC, Pontes JA, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989;141(2):257-60
79. Weiss LM, Medeiros LJ, Vickery AL JR. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6
80. Volante M, Buttigliero C, Greco E, et al. Pathological and molecular features of adrenocortical carcinoma. J Clin Pathol 2008;61:787-93
81. Fassnacht M. German Adrenal Cancer Registry: Can Registries Help to Identify Prognostic Factors. International Adrenal Cancer Symposium Ann Arbor; 2008; personal presentation
82. Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 2001;57:176-82
83. Goldblum JR, Shannon R, Kaldjian EP, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-8
84. Advani A, Vaikkakara S, GILL MS, et al. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review. J Clin Pathol 2008; in press
85. Harrison LE, Gaudin PB, Brennan ME Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181-5
86. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008;55:49-55
87. Sredni ST, Alves VA, Latorre MDO R, Zerbini MC. Adrenocortical tumours in children and adults: a study of pathological and proliferation features. Pathology 2003;35:130-5
88. Kirschner LS. Emerging Treatment Strategies for Adrenocortical Carcinoma: a new hope. J Clin Endocrinol Metab 2006;91:14-21
89. Available from: www.clinicaltrials.gov for more details
90. Vassilopoulu-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1994;73(5):1533-5